**Specifications Table**TableSubject areaBiologyMore specific subject areaNon-small cell lung cancer proteomicsType of dataMass spectrometry raw files, msf result files, Excel tables, FigureHow data was acquiredOrbitrap Fusion mass spectrometer (Thermo Scientific, Bremen, Germany), Proteome Discoverer (version 2.1.0.81) software suite (Thermo Fisher Scientific, Bremen, Germany) and SEQUEST algorithm with NCBI RefSeq human protein database (Version 75).Data formatRaw and analyzed dataExperimental factorsPrimary tissues were collected from lung adenocarcinoma and squamous cell carcinoma tissuesExperimental featuresQuantitative proteomic analysis of lung adenocarcinoma and squamous cell carcinoma tissuesData source locationBangaloreData availabilityOutput data in excel format is available here and raw data is available via a web application (ProteomeXchange) Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository with the dataset identifier [PXD008700](pride:PXD008700){#ir0015}.

**Value of the data**•This data reveals protein expression pattern associated with lung adenocarcinoma and squamous cell carcinoma tissues•Differentially expressed proteins between lung adenocarcinoma and squamous cell carcinoma may serve as potential biomarkers to distinguish these 2 subtypes•The data provides information about biological processes and pathways enriched in lung adenocarcinoma and squamous cell carcinoma

1. Data {#s0005}
=======

This dataset contains raw and processed data following LC-MS/MS analysis of lung adenocarcinoma and squamous cell carcinoma primary tissues. The processed data contains 25,998 peptides corresponding to 4342 proteins. All proteins and peptides identified in this study are listed in [Supplementary tables S1 and S2](#s0060){ref-type="sec"} respectively. We identified 610 proteins that are differentially expressed between adenocarcinoma and squamous cell carcinoma samples (≥ 2-fold). These differentially expressed proteins were further classified by gene ontology for their localization and biological processes **(**[Fig. 1 A-D](#f0005){ref-type="fig"}**)**. Further analysis of differentially expressed proteins revealed distinct alterations in pathways **(**[Tables 1A](#t0005){ref-type="table"}**-**[1B](#t0010){ref-type="table"}**)** and networks **(**[Tables 2A](#t0015){ref-type="table"}-[2B](#t0020){ref-type="table"}**)** in both adenocarcinoma and squamous cell carcinoma samples.Fig. 1Gene ontology-based annotation of differentially expressed proteins identified in lung adenocarcinoma and squamous cell carcinoma samples. (A) Classification of overexpressed proteins from lung adenocarcinoma samples (downregulated in squamous cell carcinoma) based on subcellular localization. (B) Classification of overexpressed proteins from lung adenocarcinoma samples (downregulated in squamous cell carcinoma) proteins based on molecular function. (C) Classification of downregulated proteins from lung adenocarcinoma samples (overexpressed in squamous cell carcinoma) based on subcellular localization. (D) Classification of downregulated proteins from lung adenocarcinoma samples (overexpressed in squamous cell carcinoma) proteins based on molecular function.Fig. 1Table 1ATop 5 canonical pathways enriched in upregulated proteins from lung adenocarcinoma samples (downregulated in squamous cell carcinoma).Table 1A**Canonical PathwayP-valueOverlap (%)**Leukocyte extravasation Signaling pathway2.8E-1312.6%Fcγ receptor mediated phagocytosis1.05E-1017.2%IL-8 Signaling pathway1.2E-910.7%Complement System2.53E-927.8%Production of nitric oxide and ROS in macrophages3.08E-89.8%Table 1BTop 5 canonical pathways enriched in downregulated proteins from lung adenocarcinoma samples (upregulated in squamous cell carcinoma).Table 1B**Canonical PathwayP-valueOverlap (%)**Glutathione mediated detoxification2.36E-620.8%Glutathione redox reactions I4.55E-518.2%NRF2 mediated oxidative response7.1E-54.7%Methylglyoxal Degradation2.08E-423.1%Garanazyme A Signaling4.81E-417.6%Table 2ATop 5 enriched networks in upregulated proteins from lung adenocarcinoma samples (downregulated in squamous cell carcinoma).Table 2ANetworkScoreCellular function and maintenance, Inflammatory response, Cellular movement42PTM, Protein degradation, Protein synthesis32Lipid metabolism, Small molecule biochemistry, Cell death and survival32Cellular movement, Cell to cell signaling and interactions30Lipid metabolism, Molecular transport30Table 2BTop 5 enriched networks in downregulated proteins from lung adenocarcinoma samples (upregulated in squamous cell carcinoma).Table 2B**NetworkScore**Dermatological disease and conditions, Organismal injury and abnormalities56Cellular response to therapeutics, Cell death and survival, Cell to cell signaling and interaction36Cancer, Hematological diseases21Cell morphology, RNA post transcriptional modification, Cellular development21Cellular movement, cellular growth and proliferation, cellular development19

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Tissue collection and storage {#s0015}
----------------------------------

This study was approved by the institutional review board (IRB) at All India Institute of Medical Sciences (AIIMS), New Delhi, India. The tumor tissues from 4 lung adenocarcinoma and 4 squamous cell carcinoma patients were obtained after surgical resection, histologically confirmed by an expert pathologist and stored at -80 °C till further analysis.

2.2. Tissue homogenization and protein isolation {#s0020}
------------------------------------------------

All tissues were homogenized as described previously [@bib1]. Briefly, 10 mg of tumor tissue was homogenized in 4% SDS using cell disperser (IKA works, Wilmington, NC) followed by sonication. The cell debris from tissue homogenates was removed by centrifugation at 14,000 rpm for 30 min at 4 °C. The cleared supernatant was transferred into a microfuge tube and the protein concentration determined using the BCA method.

2.3. Protein digestion and iTRAQ labelling {#s0025}
------------------------------------------

In-solution trypsin digestion of samples from both conditions was carried out as described previously [@bib2]. Equal amounts of cell lysate from all conditions were reduced using 5 mM dithiothreitol (DTT) and incubated at 60 °C for 45 mins. The reduced protein lysate was alkylated using iodoacetamide (IAA) (20 mM) and incubated for 15 mins in the dark at room temperature. To remove SDS, samples were buffer exchanged with 8 M urea followed by 50 mM TEABC to bring final concentration of SDS to 1 nano-mole. The samples were digested overnight with trypsin (Promega, Madison, WI) at an enzyme to substrate ratio of 1:20 at 37 °C. Peptides from each group were labelled using 8plex iTRAQ tags as per manufacturer׳s protocol. Peptides derived from adenocarcinoma samples were labelled with 113, 114, 115 and 116 labels while peptides from squamous cell carcinoma samples were labelled with 117, 118, 119 and 121 labels. All labels were pooled, dried and subjected to bRPLC fractionation. The workflow employed in quantitative proteomic analysis of lung adenocarcinoma and squamous cell carcinoma samples is represented in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Workflow employed for quantitative proteomic analysis of lung adenocarcinoma and squamous cell carcinoma primary tissue samples. Proteins were extracted and quantified from lung adenocarcinoma and squamous cell carcinoma primary tissue samples. In-solution trypsin digestion of equal amount of proteins from each sample was performed and peptides were labeled with iTRAQ reagents. Pooled samples were fractionated using basic reversed phase liquid chromatography for proteomic analysis. All fractions were analyzed by mass spectrometer in triplicate.Fig. 2

2.4. Basic reversed-phase liquid chromatography (bRPLC) {#s0030}
-------------------------------------------------------

Briefly, 1 mL of bRPLC solvent A (10 mMTEABC pH 8.4, Sigma Aldrich) was used to resuspend peptide mixture. This mixture was fractionated by bRPLC chromatography on a XBridge C18, 5 μm, 250 × 4.6 mm column (Waters Corporation, Milford, MA) on an Agilent 1100 LC system with a flow rate of 1 mL/min by employing an increasing gradient of bRPLC solvent B (10 mMTEABC in 90% acetonitrile, pH 8.4). A total of 96 fractions were initially collected in 96- well plates with 0.1% formic acid added to each well. The fractions were then concatenated to 6 fractions and dried using speedvac.

2.5. LC-MS/MS analysis {#s0035}
----------------------

Mass spectrometry analysis of 6 fractions was done in triplicate on Orbitrap Fusion mass spectrometer (Thermo Scientific, Bremen, Germany) interfaced with Proxeon Easy NanoLC system as described previously [@bib3]. Peptides were reconstituted in 0.1% formic acid and they were loaded on the trap column (PepMap 100 C18, Nanoviper trap column, 75 µm x 20 mm, 3 µm) using 5% Acetonitrile, 0.1% Formic acid (Solvent A). Peptide separation was done on 75 µm ID x 25 cm in-house packed analytical column packed with Reprosil-Pur 120 C18-AQ, 1.9 µm (Dr. Maisch GmbH) using a step gradient of 8% to 22% solvent B (95% Acetonitrile, 0.1% Formic acid) for 70 min and 22% to 35% for 30 min at a flow rate of 280 nl/min. Total run time was 120 min and peptides were ionized by NanoFlex ion source maintained at 1850V. Orbitrap Fusion tribrid mass spectrometer connected to Proxeon Easy nLC 1000 system was used for LC-MS/MS analysis. Peptides were analyzed using data dependent top speed mode with synchronous precursor selection enabled for MS3 analysis. Total cycle time of 3 s was used for the analysis. Survey MS scan was collected in profile mode in Orbitrap mass analyzer using 350--1600 *m*/*z* mass range with 120,000 resolutions, 4\*10^5^ AGC target and 50 ms injection time. Top most precursor ions were isolated using quadrupole mass filter with an isolation width of 0.7 Da and fragmented using collision induced dissociation with 35% normalized collision energy. MS2 spectra were acquired using Ion trap in rapid mode with 4000 AGC target and 100ms injection time. For MS3 analysis, top 10 precursor ions from MS2 spectra were isolated and fragmented using high energy collision induced dissociation (HCD) with 55% normalized collision energy. MS3 spectra were collected in Orbitrap mass analyzer with 50,000 resolutions, 1\*10^5^ AGC target and 150ms maximum injection time. Dynamic exclusion was enabled with 40 s exclusion time. Lock mass of 445.12002 m/z from ambient air was enabled for mass recalibration during the run. Each fraction was analyzed in triplicate.

2.6. Data analysis {#s0040}
------------------

Proteome Discoverer (version 2.1.0.81) software suite (Thermo Fisher Scientific, Bremen, Germany) was used for MS/MS searches and protein quantitation. SEQUEST algorithm was used for database searches with NCBI RefSeq human protein database (Version 75). The search parameters included trypsin as the protease with maximum of 2 missed cleavages allowed; oxidation of methionine was set as a dynamic modification while static modifications included carbamidomethyl (alkylation) at cysteine and iTRAQ modification. Precursor mass tolerance was set to 10 ppm and fragment mass tolerance was set to 0.6 Da. The false discovery rate (FDR) was calculated by carrying out decoy database searches and peptides scoring better than 1% FDR score cut-off were considered for further analysis. Bioinformatics analysis of differentially expressed proteins from lung adenocarcinoma and squamous cell carcinoma samples was done to classify proteins based on subcellular localization and biological function. We performed classification based on annotations in the Human Protein Reference Database (HPRD; [www.hprd.org](http://www.hprd.org){#ir0020}) [@bib4] which is in compliance with Gene Ontology (GO) standards. Pathway and network analysis of differentially expressed proteins was done using Ingenuity Pathway Analysis (IPA).
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